Thursday 23 July 2015

ADHD Therapeutics to 2020: Epidemiology, and market growth

ADHD Therapeutics to 2020: Epidemiology, and market growth
ADHD Therapeutics to 2020: Epidemiology, and market growth
Though there are cases where patents are expiring for the ADHD therapeutics, yet the market is still green about the future of the therapy. Attention deficit hyperactivity disorder (ADHD) has been in news since a decade now, and the publications pertaining to the same have steadily increased.

ADHD in children, is an attention deficit disorder where a child is unable to focus on anything for a long time. This impacts the overall effectiveness of the child and leads to frustration and sense of digestion in the child. Lately, ADHD Symptoms are also found in adults and considered as one of the more common adult psychiatric disorders.

What causes attention deficit disorder?
As it is a case with most mental disorders, it is difficult to trace the exact cause of ADHD disorder. It has nothing to do with parenting and child rearing; therefore, parents should not blame themselves for the situation. Some light can be shed that would allow tracing the symptoms of ADHD and they are genes, nutrition and food, brain injury, and also the environmental conditions.
Changes in the Therapeutics

Over the years, changes in the criteria of diagnosis has reduced the symptom threshold, which was otherwise high, and is also being accepted in clinical settings. The adults who were less privileged earlier are no more limited in treating the case, instead, are now gaining access to better treatment for ADHD condition.

A study states that almost 4.1% of the Adults in the US suffer from ADHD, and out of these cases, almost 41.3% of the cases are found to be server and definitely need treatment. The use of Extended-Release (ER) stimulant drugs have been dominantly used in treating the condition. It has been found that the treatment is almost 70-90% effective in treating the patients suffering from severe conditions.

The simulants used can be potentially be abused in some cases. Non simulants are used in patients who don’t respond well to the treatment due to poor cardiac history or also because of the need for non-simulant medication. Nevertheless, the efficiency of non-simulants are comparatively lower than the simulants.

Browse complete report with TOC:http://www.reportsandintelligence.com/adhd-therapeutics-to-2020-broadened-diagnostic-criteria-and-growing-adult-prevalence-to-drive-growth-despite-patent-expirations-market 

Current developments:

The potential gaps in the treatment are being addressed in the present pipelines. It is forecast that 3 non-simulants are entering the market during the forecast period. SHP465 is also another potential treatment that might bridge the prevailing gaps in the market.
The growing prevalence of ADHD in both children and adults will be the primary motivating factor that would propel the growth of the market, and not the drug approvals. The ever increasing population that is eligible for treatment is the undercurrent for the market growth.
Based on the prevalence of cases of ADHD, it can be safely assumed that this market has a tremendous potential for growth. The forecast states that the market could reach up to $9.4 Billion by 2020.

No comments:

Post a Comment